ESMO 2023: Better use of existing drugs increases cervical cancer survival and reduces recurrence
The INTERLACE phase III trial, funded by Cancer Research UK and UCL Cancer Trials Centre,…
The INTERLACE phase III trial, funded by Cancer Research UK and UCL Cancer Trials Centre,…
A secondary analysis from the SWOG S0931 EVEREST trial has found that in the subgroup…
A clinical trial co-led by Mount Sinai researchers is the first to show that using chemotherapy…
Belzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the…
Women living and working in places with higher levels of fine particle air pollution are…
People who engage in sexual activity or vaginal dilation after chemoradiation treatment for cervical cancer…
One of the hot topics at the VCCC Alliance Research Conference was the role of…
The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group recently held another…
Q&A with Meeting Co-Convenor Dr Ben Lawrence, Head of Oncology at University of Auckland &…
Q&A with Meeting Co-Convenor Dr Ben Lawrence, Head of Oncology at University of Auckland &…